Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS(®)) in patients with severe or moderately severe hemophilia B. The study population included 85 patients transitioning from a ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Windyga, Jerzy, Stasyshyn, Oleksandra, Lissitchkov, Toshko, Mamonov, Vasily, Serban, Margit, Rusen, Luminita, Ploder, Bettina, Tangada, Srilatha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469725/
https://www.ncbi.nlm.nih.gov/pubmed/32866032
http://dx.doi.org/10.1177/1076029620950836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469725/
https://www.ncbi.nlm.nih.gov/pubmed/32866032
http://dx.doi.org/10.1177/1076029620950836

Ejemplares similares